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Protein Kinase D1 Has a Key Role in Wound Healing
and Skin Carcinogenesis
Mohammad Rashel1, Ninche Alston1 and Soosan Ghazizadeh1
Protein kinase D (PKD) is a family of stress-responsive serine/threonine kinases implicated in the regulation of
diverse cellular functions including cell growth, differentiation, apoptosis, and cell motility. Although all three
isoforms are expressed in keratinocytes, their role in skin biology and pathology is poorly understood. We
recently identified a critical role for PKD1 during reversal of keratinocyte differentiation in culture, suggesting a
potential proproliferative role in epidermal adaptive responses. Here, we generated mice with targeted deletion
of PKD1 in the epidermis to evaluate the significance of PKD1 in normal and hyperplastic conditions. These mice
displayed a normal skin phenotype, indicating that PKD1 is dispensable for skin development and homeostasis.
Upon wounding, however, PKD1-deficient mice exhibited delayed wound re-epithelialization correlated with
a reduced proliferation and migration of keratinocytes at the wound edge. In addition, the hyperplastic and
inflammatory responses to topical phorbol ester were significantly suppressed, suggesting involvement of PKD1
in tumor promotion. Consistently, when subjected to the two-stage chemical skin carcinogenesis protocol, PKD1-
deficient mice were resistant to papilloma formation when compared with control littermates. These results
revealed a critical proproliferative role for PKD1 in epidermal adaptive responses, suggesting a potential
therapeutic target in skin wound and cancer treatment.
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INTRODUCTION
Protein kinase D (PKD) is a family of stress-responsive serine/
threonine kinases involved in the regulation of diverse
biological and pathological processes, including cell prolif-
eration, differentiation, adhesion, migration, stress-induced
cardiac hypertrophy, pathological angiogenesis, tumor cell
proliferation, and metastasis (Rozengurt, 2011). PKDs are
effectors of diacylglycerol and PKCs and are activated by a
variety of stimuli, including growth factors, neuropeptides,
hormones, and phorbol esters (Fu and Rubin, 2011). PKD
isoforms (PKD1, PKD2, and PKD3) share highly homologous
regulatory subdomains and can be activated by the same
stimuli; however, they also have distinct functions based on
their level of expression, tissue specificity, and their interacting
proteins (Fu and Rubin, 2011).
Despite recent progress in understanding the biological
functions of PKD enzymes and their involvement in disease
processes, the role of PKD in skin biology and pathology is
poorly understood. PKD1 is the most studied member of the
family. Earlier studies have shown correlation of PKD expres-
sion with proliferation status of cultured keratinocytes, sug-
gesting a proproliferative role for PKD1 in normal keratino-
cytes (Rennecke et al., 1999; Ernest Dodd et al., 2005). In
addition, PKD expression was shown to be upregulated in
mouse carcinomas and human basal cell carcinomas, although
the functional significance of PKD activation or upregulation
in these processes was not determined (Rennecke et al., 1999;
Ristich et al., 2006). These biochemical and immunohisto-
chemical studies however have been difficult to interpret
because of the presence of antibody cross-reactivity and a
failure to distinguish between individual isoforms.
We have recently shown a critical proproliferative role for
PKD1 in differentiated cultures of the epidermis during de-
differentiation in response to a low calcium switch (Jadali and
Ghazizadeh, 2010). Specific knockdown of PKD1 to 20% of
its normal level by RNA interference was sufficient to block re-
initiation of proliferation and reversal of differentiation without
affecting normal proliferation and differentiation of mouse
keratinocytes (Jadali and Ghazizadeh, 2010). Notably, neither
PKD2 nor PKD3 could compensate for the loss of PKD1
function in this process, suggesting a major role for PKD1 in
stress-induced responses in keratinocytes.
Although there is compelling evidence in cell culture
demonstrating a unique and critical role for PKD1 in kerati-
nocyte de-differentiation, the in vivo relevance of these
findings and the physiological role of PKD1 in skin remain
to be determined. In this study, we generated a conditional
knockout (cKO) of PKD1 in mouse stratified epithelia in order
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to characterize unique functions of PKD1 in skin. Our results
identified a crucial role for PKD1 in wound healing, phorbol
ester–induced hyperplasia, and skin tumor formation.
RESULTS
Epidermal PKD1 is dispensable for mouse skin homeostasis
Disruption of the mouse pkd1 gene causes embryonic lethality
(Fielitz et al., 2008); therefore, to investigate the role of PKD1
in skin epithelia, mice with targeted disruption of PKD1 in
keratinocytes (PKD1-cKO) were generated. These mice were
carrying three genetic modifications: (i) homozygously floxed
pkd1 allele (PKD1fl/fl), (ii) keratin 14 (K14)-Cre, and (iii) a Cre
reporter, flox-STOP-flox-ROSA26-yellow fluorescent protein.
PKD1-cKO mice were born at the expected Mendelian ratio
and appeared indistinguishable from their PKD1fl/fl littermates.
As shown in Figure 1, K14-regulated recombination in PKD1-
cKO mice was highly efficient and specific, resulting in
uniform yellow fluorescent protein expression in skin epithelia
(Figure 1d, lower panel). Analysis of transcript and protein
levels of three PKD isoforms confirmed efficient and specific
loss of PKD1 in PKD1-cKO keratinocytes (Figure 1a and b).
A lack of alteration in the expression of PKD2 and PKD3
indicated no compensatory upregulation of these closely
related isozymes in the absence of PKD1. The observed
residual PKD1 mRNA and protein in PKD1-cKO epidermis
is most likely reflective of PKD1 expression in melanocytes
and fibroblasts contaminating the primary epidermal cultures.
Previous studies have suggested a proproliferative and/or
antidifferentiation role for PKD1 in normal keratinocytes
(Ernest Dodd et al., 2005). Histological analysis of dorsal
skin of adult mice showed no significant difference in the skin
and hair morphology, nor in the number of proliferating
epithelial cells (Ki67 staining) between PKD1-cKO and
PKD1fl/fl mice (Figures 1c and 3d). Furthermore, analysis of
K14, an epidermal basal cell marker, and of differentiation
markers including K10, involucrin, and loricrin by either
immunofluorescence (Figure 1d) or western blot analysis (data
not shown) did not indicate any alteration in epidermal
proliferation and differentiation. Overall, these data indicated
that under normal conditions PKD1 is dispensable for skin
development and homeostasis.
Impaired wound healing by PKD1-deficient keratinocytes
PKD1 is a stress-responsive kinase and has been implicated in
cell proliferation and motility, suggesting a potential role
during wound healing (Olayioye et al., 2013). To investigate
the role of epidermal PKD1 in wound healing, the dorsal skin
of PKD1-cKO and age- and sex-matched PKD1fl/fl mice was
wounded with one 6-mm circular, splinted, full-thickness
excisional wound, and monitored daily. As shown in
Figure 2a, the kinetics of wound healing in PKD1-cKO mice
were slightly but significantly slower than control. Histological
analysis of wounds at 10 days post wounding indicated the
presence of a migrating tongue (Figure 2b, arrows) with a gap
averaging 0.96±0.47 mm (n¼ 3) in PKD1-deficient wounds,
whereas control wounds were completely re-epithelialized
(Figure 2b). Immunohistochemical analysis of 7-day-old
wounds when epidermal hyperplasia and a migrating tongue
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Figure 1. PKD1 is dispensable for mouse skin homeostasis. (a) Primary
cultures of epidermal cells isolated from PKDfl/fl or PKD1-conditional knockout
(cKO) mice and cultured for 5 days were analyzed for the expression of PKD
isozymes by semiquantitative reverse transcriptase–PCR using isozyme-specific
primers at 32 cycles for PKD1, 28 cycles for PKD2 and PKD3, and 22 cycles
for actin. (b) Western blot analysis of cell lysates described in a using an
antibody cross-reacting to PKD1/PKD2 or one specific to PKD3. Actin served
as loading control. Shown is representative of at least three experiments.
Asterisks in a and b indicate residual PKD1 expression likely contributed by
melanocytes and fibroblasts contaminating the primary epidermal cultures.
(c) Skin sections prepared from adult PKD1fl/fl or PKD1-cKO mice were
stained with either hematoxylin and eosin (H&E) for histology or
immunohistochemical staining with proliferation marker Ki67 (peroxidase,
brown nuclear staining). (d) Immunofluorescent staining of frozen skin sections
with antibody against basal cell marker (keratin 14 (K14)) or markers of early
(K10), intermediate (INV), and late (LOR) epidermal differentiation, followed
by Alexa-594-conjugated secondary antibody (red). Sections were
counterstained with 4,6-diamidino-2-phenylindole (DAPI; blue nuclear
staining). Yellow fluorescent protein (YFP) expression (green) in LOR panel is
included to show efficient and specific Cre-mediated recombination in
keratinocytes. Scale bars¼ 50mm.
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of keratinocytes are present in both groups (Figure 2c, arrows)
demonstrated a lower proliferation rate (5-bromo-20-deoxyur-
idine labeling index) for PKD1-deficient keratinocytes at the
wound edge when compared with the control (Figure 2c and
d). These data indicated a correlation between delayed wound
healing and reduced proliferative response of keratinocytes in
PKD1-cKO mice.
To confirm the involvement of PKD1 in wound re-epithe-
lialization independent of wound inflammation and contrac-
tion, a skin explant culture assay that mimics the behavior
of keratinocytes at the edge of skin wounds was used
(Mazzalupo et al., 2002). As shown in Figure 2e and f, the
areas of keratinocyte outgrowths were significantly smaller in
PKD1-cKO explants (25±8 mm2) when compared with that of
PKDfl/fl (52±12 mm2), confirming a role for PKD1 in wound
re-epithelialization. Re-epithelialization of skin wounds results
from increases in both mitotic activity and migration of
keratinocytes at the wound edge (Gurtner et al., 2008). To
determine whether keratinocyte migration was affected by the
loss of PKD1, control or PKD1-cKO explants were treated at
48 hours post seeding with mitomycin C to irreversibly block
mitosis, and the area of outgrowth was measured 5 days later.
As shown in Figure 2g, although mitomycin treatment resulted
in a significant reduction in the outgrowth area in both control
and PKD1-deficient explants, the effects were more pro-
nounced on the latter (45% in PKD1-deficient vs. 37% in
control), indicating a defect in migration of PKD1-deficient
keratinocytes. These data supported proproliferative and pro-
migratory roles for PKD1 during wound healing.
PKD1 is a major mediator of TPA-induced epidermal hyperplasia
and inflammation
To determine the significance of PKD1 in epidermal
hyperplastic responses to other stimuli, the responses of
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Figure 2. Impaired wound healing and re-epithelialization in protein kinase D1 (PKD1)-deficient mice and skin explants. (a) A 6-mm circular excisional wound
was generated in the upper back of PKD1-conditional knockout (cKO) or control mice (n¼ 6), and wound closure was monitored daily. Digital images were
obtained and the wound area was quantified and expressed as percent area of the original wound that remained open at the indicated time. Values represent
mean±SEM (n¼6), *Po0.05 PKD1-cKO versus control. (b) Healing wounds of PKD1-cKO or control mice were biopsied, sectioned at the center, and stained
with H&E for histology. Sections from two representative mice are shown with arrows indicating wound margins in PKD1-cKO. Scale bar¼ 200mm. (c, d) Sections
of 7-day-old wounds when a migrating tongue is present in both groups were stained with anti-5-bromo-20-deoxyuridine (BrdU) antibody (dark brown nuclei). The
graph in d shows the mean percentage of BrdU-positive keratinocytes in the wound edge and the migrating tongue. Values represent mean±SEM (n¼ 3),
*Po0.001 null versus control. (e) Representative PKD1fl/fl and PKD1-cKO skin explants (light brown area in the center) grown in culture for 7 days and stained for
K14 (pink staining) to show keratinocyte outgrowth. (f) K14-positive areas were measured and results are shown as mean±SEM (n¼48), Po0.01 versus control.
(g) Graph shows the area of explant outgrowth grown with or without mitomycin C treatment. Values represent mean±SEM (n¼ 24 explants from four mice).
*Po0.001 PKD1-cKO versus PKD1fl/fl.
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PKD1-deficient epidermis to a tumor promoter 12-O-tetra-
decanoyl-phorbol-13-acetate (TPA) was examined. TPA is a
diacylglycerol analog and a known inducer of PKD activation
in mouse keratinocytes (Ernest Dodd et al., 2005; Jadali and
Ghazizadeh, 2010). Topical application of TPA is known to
induce hyperplasia and inflammation, and is necessary for
skin tumor development in two-stage chemical carcinogenesis
(Rundhaug and Fischer, 2010). To determine the potential role
of PKD1 in TPA-induced mitogenic responses in skin, PKD1-
cKO and PKDfl/fl were treated with a single dose of TPA or
acetone (control) and analyzed 48 hours later. As shown in
Figure 3, a single dose of TPA in PKD1fl/fl skin induced a
robust proliferative response leading to a 4-fold increase in the
number of Ki67-positive keratinocytes and more than a 5-fold
increase in the epidermal thickness. In PKD1-cKO mice,
however, these responses were blunted with only a 2-fold
increase in proliferating basal keratinocytes and in the epi-
dermal thickness. In addition, analysis of skin sections showed
a marked suppression of TPA-induced inflammation in PKD1-
cKO mice (Figure 3a). Immuofluorescent analysis of skin
sections for S100A9, which is constitutively expressed on
monocytes and neutrophils (Lagasse and Weissman, 1992),
showed a 5-fold reduction in the number of infiltrating
leukocytes in PKD1-cKO mice (Figure 3e and f). These data
indicate a critical role for PKD1 as a positive regulator of
epidermal hyperplasia and inflammation in response to
phorbol esters, suggesting a role in tumor promotion.
PKD1-deficient mice are resistant to tumor formation in
two-stage chemically induced skin carcinogenesis
To examine the potential effects of epidermal PKD1 in tumor
promotion, two-stage chemical carcinogenesis experiments
were carried out in PKD1-cKO and their normal littermates.
The use of 7,12-dimethylbenz[a]anthracene, to introduce
oncogenic mutations primarily on the Hras1 gene, and TPA
as tumor promoters, to allow selective outgrowth of initiated
cells, is a well-established chemical carcinogenic treatment
that leads primarily to papilloma formation in the skin
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Figure 3. Suppression of 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced responses in protein kinase D1 (PKD1)-conditional knockout (cKO) mouse skin.
PKD1fl/fl or PKD1-cKO dorsal skin was treated with a single dose of acetone (carrier control) or TPA (5 nmol/100ml acetone), and 48 hours later skin biopsies
were taken and processed for histological analysis. Skin sections were stained with (a) hematoxylin and eosin (H&E) for histology, (c) antibody against
proliferation marker Ki67 (peroxidase, dark brown staining), or (e) antibody against leukocyte marker S100A9 followed by Alexa-594-conjugated secondary
antibody (red). 4,6-Diamidino-2-phenylindole (DAPI; nuclear blue staining) was used as a counterstain. A representative of six mice from two separate
experiments is shown. Scale bars¼ 100mm. Graphs show the average thickness of the epidermis (b), the number of Ki67-positive basal keratinocytes (d),
and the number of inflammatory S100A9-positive cells (f) in skin sections. Six different regions in sections prepared from three different mice were quantified.
Values represent meanþ SEM (n¼3); *Po0.001 TPA-treated PKD1-cKO versus TPA-treated control.
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(Abel et al., 2009). Groups of 15 mice at 7–8 weeks of age
were treated with 7,12-dimethylbenz[a]anthracene, followed
a week later by twice-weekly TPA for 20 weeks. Animals were
examined weekly to determine tumor incidence and multi-
plicity. Six weeks after the last TPA treatment, tumors were
quantified, harvested, and analyzed. As shown in Figure 4,
mice lacking PKD1 in the epidermis were refractory to
papilloma formation. Although all control mice develop
tumors by 16 weeks of promotion, 460% of PKD1-deficient
mice did not develop any tumor during the entire 26 weeks of
observation (Figure 4a and b). In addition, the average number
and size of tumors in tumor-bearing PKD1-cKO mice were
markedly reduced (Figure 4c and d). Histological analysis of
tumors revealed that most of the tumors formed in both groups
were benign papillomas and keratoacanthomas (data not
shown). At 26 weeks, the frequency of malignant conversion
of these benign tumors was o3% and was restricted to the
control mice. Malignant conversion in PKD1-cKO mice,
however, may have remained undetected because of the
lower total number of tumors developed in these mice.
The PKD1-cKO mice resistance to carcinogen-induced tumor-
igenesis was not the result of increased apoptosis in PKD1-
deficient keratinocytes, as the number of apoptotic keratinocytes
following 24 hours of 7,12-dimethylbenz[a]anthracene treat-
ment was comparable between the two groups (data not
shown). These data identified PKD1 as the key transducer of
the tumor-promoting effects of TPA in chemically induced
skin carcinogenesis.
DISCUSSION
Most of the functions assigned to PKD1 have been character-
ized in cell culture systems, and their in vivo relevance has yet
to be determined. By using a conditional knockout of PKD1
targeted to stratified epithelia, we investigated the nonredun-
dant role of PKD1 in the epidermis. Although PKD1 was found
to be dispensable for skin development and homeostasis, our
study identified a critical role for this enzyme during wound
healing and in the TPA-induced hyperplastic/inflammatory
responses that are necessary for tumor development. Our
findings are consistent with the PKD function as a stress-
responsive kinase and provide direct genetic evidence sup-
porting a proproliferation role for PKD1 in skin tumor devel-
opment. PKD isoforms share high sequence homology, and all
isoforms could be activated by TPA (Fu and Rubin, 2011).
Despite expression of all three PKD isoforms in mouse
keratinocytes (Jadali and Ghazizadeh, 2010), disruption of
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Figure 4. Reduced skin tumor formation in protein kinase D1 (PKD1)-deficient mice. (a) The incidence of tumors in groups of PKD1-conditional knockout (cKO)
and control mice (n¼ 15 per group) subjected to 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA) protocol and
monitored weekly for tumors 41.5 mm in diameter. (b) Representative mice from each group showing reduced tumor number and volume in PKD1-cKO
at 26 weeks. Arrows in the lower panel indicate small tumors developed in PKD1-deficient mice. (c) Kinetics of tumor multiplicity using 15 mice per genotype.
Po0.0001 for overall differences and Po0.001 for differences between PKD1-cKO mice and PKD1fl/fl at each week. (d) Graph showing the average size
of tumors developed per mouse. Error bars represent SEM. Po0.001 PKD1-cKO mice versus PKD1fl/fl.
M Rashel et al.
PKD1 in Epidermal Adaptive Responses
906 Journal of Investigative Dermatology (2014), Volume 134
the PKD1 gene alone resulted in marked reduction in TPA-
induced responses and tumor promotion. This indicated that
PKD2 and PKD3 cannot fully compensate for the loss of PKD1
function during this process. The TPA-induced responses in
PKD1-cKO mice, however, were not completely blocked and
may reflect some redundant functions of PKD2 and PKD3
during tumor promotion.
Previous studies using primary cultures of mouse keratino-
cytes have suggested a proproliferative and/or antidifferentia-
tion role for PKD1 in normal keratinocytes (Ernest Dodd et al.,
2005). The normal skin architecture and unaltered expression
of proliferation and differentiation markers in PKD1-deficient
epidermis did not support this hypothesis. Moreover, the
growth and differentiation of primary cultures of PKD1-
deficient keratinocytes were comparable to that of control
littermates, arguing against a general proproliferation/
antidifferentiation role for PKD1 in keratinocytes (data not
shown). This is consistent with our previous studies using
small inhibitory RNA to knock down PKD1 in mouse
keratinocytes (Jadali and Ghazizadeh, 2010). Although there
was no compensatory upregulation of PKD2 and PKD3 in
PKD1-null keratinocytes (Figure 1), the possible functional
redundancy of PKDs or other stress-responsive kinases acting
on common targets during normal growth and differentiation
of keratinocytes cannot be excluded.
Using two complementary ex vivo and in vivo approaches,
we showed that disruption of PKD1 impaired re-epithelializa-
tion during wound healing. PKD1 has been implicated as an
inhibitor or a promoter of directed cell migration depending
on the cell type and the experimental condition (Olayioye
et al., 2013). Consistent with our studies, PKD1 has been
shown to be involved in the regulation of hemidesmosome
dynamics through direct phosphorylation of integrin b4 on
its signaling domain, a process important in promoting
keratinocyte migration and proliferation (Nikolopoulos et al.,
2005; Frijns et al., 2012). In addition to the PKD1 regulation of
hemidesomosomes in the basal keratinocytes, PKD1 has been
shown to have a distinct proproliferation function during
reversal of differentiation in keratinocytes (Jadali and
Ghazizadeh, 2010). It is plausible to assume that PKD1
activation in differentiated cells in vivo may increase the
size of proliferative cell pool during wound healing where
normal differentiation process may be reversed (Morasso and
Tomic-Canic, 2005).
PKDs are involved in a diverse set of signaling pathways
important to tumor development and cancer progression and
have been shown to be dysregulated in several cancer types
(LaValle et al., 2010; Sundram et al., 2011). Our study
underlines a role for PKD1 in skin tumor formation. The
two-stage chemical carcinogenesis is widely used to study
the mechanism of epithelial carcinogenesis (Rundhaug
and Fischer, 2010). Our data identified PKD1 as a major
downstream target of TPA/diacylglycerol and a key mediator
of skin tumor promotion. TPA is known to activate PKDs
via a PKC-dependent mechanism. The PKCs directly bind,
phosphorylate, and activate PKDs, although classical PKCs,
specifically PKCa, can also activate PKDs (Rozengurt et al.,
2005). d, e, and Z isoforms are expressed in mouse
keratinocytes; however, d and Z isoforms are thought to be
antitumorigenic, and the role of PKCe appears to be more
complex (Rundhaug and Fischer, 2010). Mice overexpressing
PKCe have been shown to be resistant to papilloma formation
but develop papilloma-independent metastatic carcinomas
independent of TPA treatment (Reddig et al., 2000). These
studies suggest, at least in part, distinct roles for PKCe and
PKD1 in tumor formation. Another highly expressed PKC in
the epidermis, PKCa, is a major target for TPA in differentiated
keratinocytes (Dlugosz et al., 1994). Similar to PKD1,
disruption of PKCa gene in mice has been shown to result
in impaired TPA- and wound-induced epidermal hyperplasia.
However, PKCa-null mice were more susceptible to tumor
formation (Hara et al., 2005). The apparent divergence of
PKC and PKD1 signaling in response to TPA may be explained
by distinct substrate specificity of PKCs and PKDs or by the
time- and context-dependent activation of PKD1 by PKC-
dependent and -independent mechanisms, as previously
described (Jacamo et al., 2008; Rybin et al., 2009). Clearly,
further studies are necessary to delineate the mechanism by
which PKD1 mediates its proproliferative effects in the
epidermis.
In summary, the results presented here underline the
importance of PKD signaling in epidermal adaptive responses
including wound healing and skin carcinogenesis, suggesting
another therapeutic target to alter wound healing or suppress
skin tumor formation. Consistent with our findings, PKD1
signaling has been implicated in the cancer-preventive
activity of green tea constituents in mouse skin (Chiou et al.,
2013).
MATERIALS AND METHODS
Mice
PKD1-cKO mice were carrying three genetic modifications: (i) homo-
zygously floxed pkd1 allele from exons 12 to 14 encoding part of the
catalytic domain of PKD1, which is essential for kinase function and
PKD mRNA stability (Fielitz et al., 2008); (ii) K14-Cre, which targets
Cre recombinase to keratinocytes (Dassule et al., 2000); and (iii) a Cre
reporter, flox-STOP-flox-ROSA26-yellow fluorescent protein (Srinivas
et al., 2001), to identify PKD1-cKO mice from PKD1fl/fl littermates.
The specific knockdown of PKD1 in primary cultures of the epidermis
was verified with semiquantitative reverse transcriptase–PCR and
immunoblotting. Total RNA was isolated using Trizol Reagent (Life
Technologies, Grand Island, NY) and analyzed using the One Step
RT-PCR kit (Qiagen,Valencia, CA). The following primers were used:
PKD1, 50-CACTGTGACCTCAAGCCAGA-30 and 50-CCAACAGACCA
CATGTCCAG-30; PKD2, 50-AGAGTGCTCTCCATGCCAGT-30 and
50-GACAGCGGGATTTCCTTGTA-30; PKD3, 50-AATGTGCAGGGTC
AAAGTCC-30 and 50-CCCCTACTGCCATCACTGTT-30. RNA levels of
the target genes were normalized against the b-actin transcript levels.
PKD1 and PKD2 protein levels in 30mg of protein lysates were
analyzed by immunoblotting using antibodies against PKD1/2
(CS-2052), PKD3 (CS-5655; Cell Signaling Technologies, Danvers,
MA), and b-actin (SC-1615) as a loading control. PKD1-cKO and
control mice were maintained on a mixed 129/SvC57BL/6 back-
ground. Animals were housed under standard conditions, and all
animal experiments were conducted in accordance with institutional
guidelines set forth by the State University of New York.
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Wound-healing analysis
For in vivo analysis, a well-established and reproducible excisional
wound-healing model was used (Galiano et al., 2004). Dorsal hair of
7- to 9-week-old mice (age and sex matched) was clipped and a full-
thickness 6-mm circular wound was generated in the upper back.
A 10-mm circular splint was placed around the wound perimeter and
secured with Krazy glue and six interrupted sutures to fix the splint
to the skin. Wounds were covered with sterile Tegaderm dressings
(3M Healthcare, St Paul, MN), which were changed every other day
until wounds were closed. Digital images were obtained at the time
of dressing changes. Wound area was quantified using the splint to
normalize the wound size. Wound area was calculated as percent
area of the original wound. Representative wounds were biopsied
following a 2-hour 5-bromo-20-deoxyuridine pulse (50mg g–1 body
weight), bisected, and fixed in 10% formalin for routine histological
processing and immunostaining.
For ex vivo analysis, the quantitative explant outgrowth assay of
mouse skin was used as previously described (Mazzalupo et al.,
2002). Briefly, dorsal skin of 2-day-old pups were removed, and
4-mm punch biopsies were cultured for 7 days. To assess keratinocyte
outgrowth, explants were immunostained using an antibody against
K14 and the Supersensitive IHC Detection kit (Biogenex Laboratories,
San Ramon, CA). Plates were photographed and the total area of
outgrowth was measured using the NIH-Image J software (NIH,
Bethesda, MD). A subset of explants were treated with mitomycin
C (5 ug ml–1 for 2 hours; Sigma-Aldrich, St Louis, MO) or phosphate-
buffered saline (as controls) at 48 hours post seeding and analyzed 5
days later as described above.
TPA induction of epidermal hyperplasia
The dorsal skin of 7- to 9-week-old male mice was shaved, and on the
next day the mice were treated with either a single dose of 5 nmol
TPA (LC Laboratories, Woburn, MA) in 100ml of acetone or 100ml of
acetone (carrier control). Two days later, mice were killed and the
treated skin was biopsied and fixed for histological processing. Skin
samples were analyzed following hematoxylin and eosin staining or
immunostaining using antibodies specific for Ki67 (proliferation
marker; Novocastra, New Castle, UK) or S100A9 (leukocyte marker;
Axxzel Biosystem LLC, Houston, TX). The epidermal thickness was
measured in sections stained with hematoxylin and eosin at a
minimum of six different regions in sections prepared from three
different mice.
Two-stage chemical carcinogenesis experiments
The dorsal skin of 7- to 8-week-old mice (10 males and 5 females per
group) was shaved, and a day later the mice were treated with a
single application of 7,12-dimethylbenz[a]anthracene (100mg in
200ml of acetone; Sigma Aldrich) as an initiating agent. A week
later, mice were treated with TPA (20 nmol/200ml acetone) twice
weekly for 20 weeks to promote tumor formation. There was no
significant difference between the average number of tumors devel-
oped in male and female mice. Tumors, defined as raised lesions with
a minimum of 1.5 mm diameter, were assessed weekly for 26 weeks.
At this time, tumors were harvested for further analysis.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism version
5.0 (GraphPad Software, La Jolla, CA). Student’s t-test was used for
comparing two groups of data. For analysis of tumor incidence,
comparison of the curves showing the mice with tumors was
performed using log-rank w2 test. Tumor multiplicity was analyzed
using repeated-measures analysis of variance for overall differences
between the two groups and Mann–Whitney test for comparing
differences at each week between PKDfl/fl and PKD1-cKO. Only
values with Po0.05 were accepted as significant.
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